Herceptin acts as an anti-angiogenic cocktail
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Malignant tumours secrete factors that enable them to commandeer their own blood supply (angiogenesis), and blocking the action of these factors can inhibit tumour growth. But because tumours may become resistant to treatments that target individual angiogenic factors by switching over to other angiogenic molecules, a cocktail of multiple anti-angiogenic agents should be more effective. Here we show that herceptin, a monoclonal antibody against the cell-surface receptor HER2 (for human epidermal growth factor receptor-2; ref. 4), induces normalization and regression of the vasculature in an experimental human breast tumour that overexpresses HER2 in mice, and that it works by modulating the effects of different pro- and anti-angiogenic factors. As a single agent that acts against multiple targets, herceptin, or drugs like it, may offer a simple alternative to combination anti-angiogenic treatments.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Certain molecularly targeted agents, such as the anti-HER2 antibody trastuzumab, and metronomic chemotherapy can also induce vascular normalization via upregulation of thrombospondin expression28,116,117.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [116]
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184
Self-citationLeakage-Resistant Blood Vessels in Mice Transgenically Overexpressing Angiopoietin-1
Thurston, G., Suri, C., Smith, K., McClain, J., Sato, T. N., Yancopoulos, G. D., & McDonald, D. M. (1999) · Science · doi:10.1126/science.286.5449.2511 · Cited by 1,359
Tumor Induction of VEGF Promoter Activity in Stromal Cells
Fukumura, D., Xavier, R., Sugiura, T., Chen, Y., Park, E.-C., Lu, N., Selig, M., Nielsen, G., Taksir, T., Jain, R. K., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81731-6 · Cited by 996
Self-citationThrombospondins as matricellular modulators of cell function
Bornstein, P. (2001) · Journal of Clinical Investigation · doi:10.1172/jci12749 · Cited by 470
Allgayer, H., Babic, R., Gruetzner, K. U., Tarabichi, A., Schildberg, F. W., & Heiss, M. M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.11.2201 · Cited by 276
‘Accidental’ anti-angiogenic drugs
Kerbel, R. S., Viloria-Petit, A., Klement, G., & Rak, J. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00092-7 · Cited by 182
Angiogenic Heterogeneity: Regulation of Neoplastic Angiogenesis by the Organ Microenvironment
Fidler, I. J. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.14.1040 · Cited by 109
Jain, R. K., & Carmeliet, P. (2001) · Scientific American · doi:10.1038/scientificamerican1201-38 · Cited by 94
Self-citation
Research works printed but not linked: 1
- Jain, R. K., Munn, L. L. & Fukumura, D. Nature Rev. Cancer (in the press).
Cited by
Items 401–500 of 622
Kunitomo, K., Inoue, S., Ichihara, F., Kono, K., Fujii, H., Matsumoto, Y., & Ooi, A. (2004) · Human Pathology · doi:10.1016/j.humpath.2003.05.003 · Cited by 13
Li, Y., Qin, J., Chen, G., Wu, W., & Sun, X. (2024) · International Journal of Clinical Oncology · doi:10.1007/s10147-024-02472-9 · Cited by 12
Maae, E., Andersen, R. F., Steffensen, K. D., Jakobsen, E. H., Brandslund, I., Sørensen, F. B., & Jakobsen, A. K. M. (2012) · PubMed · Cited by 12
Manso, L., Valdiviezo, N., Sepúlveda-Sánchez, J. M., Ciruelos, E., Mendiola, C., Ghanem, I., Vega, E., Manneh, R., Dorta, M., & Cortés-Funes, H. (2012) · Clinical & Translational Oncology · doi:10.1007/s12094-012-0954-4 · Cited by 12
Chung, A. P., Choi, M. P., Han, B.-C., Bose, S., Zhang, X., Medina‐Kauwe, L. K., Sims, J. D., Murali, R., Taguiam, M., Varda, M. M., et al. (2015) · Clinical Breast Cancer · doi:10.1016/j.clbc.2015.06.001 · Cited by 12
Improving the efficacy of trastuzumab in breast cancer
Suzuki, E., & Toi, M. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00455.x · Cited by 13
Rodrigues, L. M., Stubbs, M., Robinson, S. P., Newell, B., Mansi, J., & Griffiths, J. R. (2004) · Magnetic Resonance Materials in Physics Biology and Medicine · doi:10.1007/s10334-004-0070-8 · Cited by 12
Kałas, W., Klement, P., & Rak, J. W. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.06.123 · Cited by 13
Targeting HER2 in breast cancer: overview of long-term experience
Higa (2009) · International Journal of Women s Health · doi:10.2147/ijwh.s5647 · Cited by 11
Blood Flow and Tumour-Induced Angiogenesis: Dynamically Adapting Vascular Networks
Chaplain, M. A. J., McDougall, S. R., & Anderson, A. R. A. (2011) · Springer eBooks · doi:10.1007/978-1-4614-0052-3_8 · Cited by 11
Biological signature of HER2-positive breast cancer
Lindqvist, B. M. (2013) · Cited by 31
Jain, R. K., Martin, J. D., Chauhan, V. P., & Duda, D. G. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00008-6 · Cited by 16
Self-citationThe emerging role of Oxadiazole derivatives as VEGFR and EGFR inhibitors in Cancer therapy
Nath, R., Debnath, B., Chakraborty, A., Khan, S. A., Maity, A., & Akhtar, M. J. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.109140 · Cited by 10
Tan, P., & Lota, A. S. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.15.2639 · Cited by 10
Shammas, R. L., Cho, E. H., Glener, A. D., Poveromo, L., Mundy, L. R., Greenup, R. A., Blackwell, K., & Hollenbeck, S. T. (2017) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2017.08.023 · Cited by 13
Karrobi, K., Tank, A., Tabassum, S. M., Pera, V., & Roblyer, D. M. (2019) · Journal of Biophotonics · doi:10.1002/jbio.201800379 · Cited by 9
Impact of trastuzumab on wound healing in experimental glaucoma surgery
Turgut, B., Eren, K., Akın, M. M., Can, N., & Demır, T. (2014) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.12359 · Cited by 10
Harada, S., YANAGISAWA, M., Kaneko, S. J., Yorozu, K., Yamamoto, K., Moriya, Y., & Harada, N. (2015) · Molecular and Clinical Oncology · doi:10.3892/mco.2015.609 · Cited by 11
Potential therapeutic implications of intracrine angiogenesis
Ré, R. N., & Cook, J. L. (2007) · Medical Hypotheses · doi:10.1016/j.mehy.2006.10.065 · Cited by 10
Recent advances in the design and discovery of small-molecule therapeutics targeting HER2/neu
Dayam, R., Grande, F., Al‐Mawsawi, L. Q., & Neamati, N. (2007) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.17.1.83 · Cited by 10
Grothey, A. F. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.08.004 · Cited by 10
Plosker, G. L., & Keam, S. J. (2006) · BioDrugs · doi:10.2165/00063030-200620040-00007 · Cited by 10
Stroma cells: a novel target of herceptin activity.
Corsini, C. A., Mancuso, P., Paul, S., Burlini, A., Martinelli, G., Pruneri, G., & Bertolini, F. (2003) · PubMed · Cited by 10
McDougall, S. R., Chaplain, M. A. J., Stéphanou, A., & Anderson, A. R. A. (2010) · Mathematical Modelling of Natural Phenomena · doi:10.1051/mmnp/20105108 · Cited by 12
Monoclonal Antibodies, Small Molecule Inhibitors and Antibody-drug Conjugates as HER2 Inhibitors
Li, X., Liu, C., & Rao, G. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200908112847 · Cited by 11
Xu, J., Kang, F., Wang, W., Liu, S., Xie, J., & Yang, X. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/7490279 · Cited by 9
Sebahar, P. R., Willardsen, J. A., & Anderson, M. (2009) · Current Bioactive Compounds · doi:10.2174/157340709787580919 · Cited by 9
Neuregulin-1 Signaling in the Pathogenesis of Chemotherapy-Induced Heart Failure
Lenneman, C. G. (2014) · Current Heart Failure Reports · doi:10.1007/s11897-014-0193-9 · Cited by 9
Saito, Y., Hironori Nakagami, A., Kurooka, M., Takami, Y., Kikuchi, Y., Hayashi, H., Nishikawa, T., Tamai, K., Morishita, R., Azuma, N., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210824 · Cited by 9
Chorn, N. (2006) · Oncology nursing forum · doi:10.1188/06.onf.265-272 · Cited by 9
Targeting ERBB Receptors in Cancer
Hynes, N. E. (2007) · Springer eBooks · doi:10.1007/978-3-540-31209-3_4 · Cited by 12
Resistance to Anti-HER2 Therapies in Gastrointestinal Malignancies
Mo, C., Sterpi, M., Jeon, H., & Bteich, F. (2024) · Cancers · doi:10.3390/cancers16162854 · Cited by 8
“These intracellular mechanisms may include inhibiting HER2-mediated cell signaling pathways like AKT and ERK, suppressing HER2 cleavage, interfering with DNA damage repair processes and inhibiting angiogenesis by reducing VEGF production [27–37].”
BackgroundKönigsberg, R., Maierhofer, J., Steininger, T., Kienzer, G., & Dittrich, C. (2013) · Radiology and Oncology · doi:10.2478/raon-2013-0083 · Cited by 8
Angiogenic Signaling Pathways and Anti-angiogenic Therapies in Human Cancer
Nasir, A. (2018) · Springer eBooks · doi:10.1007/978-3-319-95228-4_19 · Cited by 8
Characterization of a novel trastuzumab resistant human breast cancer cell line
Balazs, M. (2010) · Frontiers in Bioscience-Elite · doi:10.2741/e119 · Cited by 10
Role of Microenvironment on Gene Expression, Angiogenesis and Microvascular Function in Tumors
Fukumura, D. (2005) · Springer eBooks · doi:10.1007/1-4020-3414-8_2 · Cited by 8
Self-citationMeasuring Vascular Permeability in Mice
Jain, R. K., Munn, L. L., & Fukumura, D. (2013) · Cold Spring Harbor Protocols · doi:10.1101/pdb.prot074344 · Cited by 10
Self-citationAlghafar, D. A., Younos, I., Al-Baimani, K. S., Al-Salhi, D., Al-Riyami, A. B., Rizvi, S. Z. H., & Buckley, N. E. (2020) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155220919888 · Cited by 7
Kim, D.-M., Lee, S.-Y., Lim, J.-C., Cho, E.-H., & Park, U.-J. (2023) · BMC Cancer · doi:10.1186/s12885-023-11161-1 · Cited by 7
Michaelson, M. D., Iliopoulos, O., McDermott, D. F., McGovern, F. J., Harisinghani, M. G., & Oliva, E. (2008) · New England Journal of Medicine · doi:10.1056/nejmcpc0802449 · Cited by 8
Vascular and Interstitial Biology of Tumors
Jain, R. K., & Duda, D. G. (2008) · Elsevier eBooks · doi:10.1016/b978-0-443-06694-8.50011-7 · Cited by 7
Self-citationSoltaninasab, S., Ahmadzadeh, M., Shahhosseini, S., & Mohit, E. (2021) · Protein Expression and Purification · doi:10.1016/j.pep.2021.106004 · Cited by 7
Krzykawska-Serda, M., Szczygieł, D., Gaweł, S., Drzał, A., Szczygieł, M., Kmieć, M. M., Mackiewicz, A. A., Kiéda, C., & Elas, M. (2023) · PLoS ONE · doi:10.1371/journal.pone.0285318 · Cited by 6
Ujlaky‐Nagy, L., Szöllõsi, J., & Vereb, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115978 · Cited by 6
Mild hyperthermia influence on Herceptin ® properties
Escoffre, J., Deckers, R., Sasaki, N., Bos, C., & MOONEN, C. T. W. (2015) · Radiology and Oncology · doi:10.2478/raon-2014-0045 · Cited by 6
Trastuzumab-DM1: A Review of the Novel Immuno-Conjugate for HER2- Overexpressing Breast Cancer
Barginear, M. F., & Budman, D. R. (2009) · The Open Breast Cancer Journal · doi:10.2174/1876817200901010025 · Cited by 6
Antibodies and antibody-fusion proteins as anti-angiogenic, anti-tumor agents
Calfa, C., Rosenblatt, J. D., Cho, H., Webster, K. A., & Shin, S. U. (2006) · Update on Cancer Therapeutics · doi:10.1016/j.uct.2006.05.001 · Cited by 6
Macroalgal Polysaccharides in Biomimetic Nanodelivery Systems
Geškovski, N., Dimchevska, S., & Goračinova, K. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190423155116 · Cited by 6
Normalization of Tumor Vasculature and Microenvironment
Jain, R. K., Duda, D. G., Batchelor, T. T., Sorensen, A. G., & Willett, C. G. (2008) · Springer eBooks · doi:10.1007/978-0-387-71518-6_24 · Cited by 6
Self-citationAdvances of Haloperoxidases-Catalyzed Green Halogenation Reactions
Zeng, Z., Sang, X., Yuan, B., Wu, M., & Zhang, W. (2021) · Chinese Journal of Organic Chemistry · doi:10.6023/cjoc202009007 · Cited by 6
Inhibitors of Tumor Angiogenesis
Harris, A. L., & Generali, D. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-396521-9.00010-3 · Cited by 7
Johnson, T. A., & Singla, D. K. (2018) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2018-0005 · Cited by 9
Normalization of Tumor Vasculature and Microenvironment
Jain, R. K., Batchelor, T. T., Duda, D. G., & Willett, C. G. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-184-0_15 · Cited by 6
Self-citationHER-2/neu Cancer Vaccines: Present Status and Future Prospects
Kaumaya, P. T. P. (2006) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-005-9000-5 · Cited by 6
Clinical Updates on EGFR/HER Targeted Agents in Early-Stage Breast Cancer
Macrinici, V., & Romond, E. H. (2010) · Clinical Breast Cancer · doi:10.3816/cbc.2010.s.006 · Cited by 6
Antibody therapy for early-stage breast cancer: trastuzumab adjuvant and neoadjuvant trials
Mehra, R., & Burtness, B. A. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.6.9.951 · Cited by 6
Growth Factors, Receptors, and Kinases: Their Exploration to Target Cancer
Brown, J. G., & Gibson, S. B. (2006) · Springer eBooks · doi:10.1007/0-387-23695-3_8 · Cited by 6
Reply to 'Recognition of tumor blood vessel normalization as a new antiangiogenic concept'
Jain, R. K. (2004) · Nature Medicine · doi:10.1038/nm0404-329b · Cited by 6
Self-citationLack of Effects of HER-2/neu on Prognosis in Colorectal Cancer: a Meta-analysis
Han, J. S., Meng, Q., Liu, X., Xi, Q., Zhuang, Q., & Wu, G. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.14.5551 · Cited by 5
Dassler, K., Scholle, F.-D., & Schütz, G. (2013) · Magnetic Resonance in Medicine · doi:10.1002/mrm.24815 · Cited by 5
Waterhouse, D., Yapp, D. T. T., Verreault, M., Anantha, M., Sutherland, B. W., & Bally, M. B. (2011) · Nanomedicine · doi:10.2217/nnm.11.140 · Cited by 6
Antibody-Mediated Receptor Endocytosis: Harnessing the Cellular Machinery to Combat Cancer
Tarcic, G., & Yarden, Y. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6528-7_17 · Cited by 6
Angiogenesis Signaling Pathways as Targets in Cancer Therapy
Whipple, C. A., & Korc, M. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-374145-5.00333-8 · Cited by 7
Molecular Biology of Breast Cancer
Snoj, N., Dinh, P., Bedard, P. L., & Sotiriou, C. P. (2009) · Elsevier eBooks · doi:10.1016/b978-0-12-374419-7.00025-1 · Cited by 7
Cancer drugs and diabetic retinopathy: a dangerous, underestimated association
Milluzzo, A., Manuella, L., Frittitta, L., & Sciacca, L. (2024) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2023.43 · Cited by 4
Piccolo, C. L., Celli, I., Bandini, C., Tommasiello, M., Sammarra, M., Faggioni, L., Cioni, D., Zobel, B. B., & Neri, E. (2024) · Cancers · doi:10.3390/cancers16050870 · Cited by 4
Mechanisms of resistance to trastuzumab: an updated review
Zhang, Y., & Zhang, J. (2010) · The Chinese-German Journal of Clinical Oncology · doi:10.1007/s10330-010-0700-8 · Cited by 4
Pandey, A. K., & Brufsky, A. (2018) · Clinical Breast Cancer · doi:10.1016/j.clbc.2018.09.010 · Cited by 5
The Role of Oncogene Activation in Tumor Progression
Gray, M. J., & Gallick, G. E. (2010) · Springer eBooks · doi:10.1007/978-90-481-3725-1_2 · Cited by 6
Zhu, J., Yu, X., & Mi, M. (2006) · Chinese Journal of Cancer Research · doi:10.1007/s11670-006-0083-0 · Cited by 4
A novel mouse monoclonal antibody targeting ErbB2 suppresses breast cancer growth
Kawa, S., Matsushita, H., Ohbayashi, H., Semba, K., & Yamamoto, T. S. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.04.118 · Cited by 4
Damiani, E., Pierpaoli, E., Orlando, F., Donati, A., & Provinciali, M. (2014) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12343 · Cited by 4
Targeting angiogenesis with monoclonal antibodies
Bicknell, R. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl241 · Cited by 4
Novel Therapies to Overcome HER2 Therapy Resistance in Breast Cancer
Nahta, R. (2019) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-030-21477-7_7 · Cited by 3
Corte-Torres, M. D., Rodil, J. A., Vázquez, J., García, L. R., Rodrı́guez, J. C., Bongera, M., Fernández, J. C. F., González, L. O., Lamelas, M. L., Allende, M., et al. (2005) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-005-0022-3 · Cited by 4
Angiostatin up-regulation in gastric cancer cell SGC7901 inhibits tumorigenesis in nude mice
Wu, K. (2003) · World Journal of Gastroenterology · doi:10.3748/wjg.v9.i1.59 · Cited by 4
Synergistic anticancer effects of Chrysin and trastuzumab in HER2-Positive breast cancer cells
Jafari, S., Ostadrahimi, A., Farjami, A., & Montazersaheb, S. (2025) · Scientific Reports · doi:10.1038/s41598-025-25098-x · Cited by 3
Towards a therapeutic breast cancer vaccine: the next steps
Emens, L. A. (2005) · Expert Review of Vaccines · doi:10.1586/14760584.4.6.831 · Cited by 3
Qu, F., Liu, Q., Lu, R., & Li, W. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1245701 · Cited by 3
Trastuzumab Therapy and ERBB2 Genotype
Dean, L., & Kane, M. S. (2021) · Europe PMC (PubMed Central) · Cited by 6
Molecular Imaging of Tumor Angiogenesis
McDermott, S., & Guimarães, A. R. (2012) · InTech eBooks · doi:10.5772/32202 · Cited by 3
Modes of Neovascularization in Tumors and Clinical Translation of Antiangiogenic Therapy
Jain, R. K., Fukumura, D., & Duda, D. G. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-386456-7.05502-7 · Cited by 3
Self-citationAnti-Tumor Effect and Its Mechanism of Vaccaria segetalis on Mouse Inoculated H22 Solid Carcinoma
Gao, Y., Qiu, L.-Y., Kang, X.-X., Wang, H., Liu, L., Feng, L., & Jin, J. (2010) · International Conference on Bioinformatics and Biomedical Engineering · doi:10.1109/icbbe.2010.5517710 · Cited by 3
Garnock-Jones, K. P., Keating, G. M., & Scott, L. J. (2010) · BioDrugs · doi:10.2165/11204680-000000000-00000 · Cited by 3
Antiangiogenesis Therapy in Breast Cancer
Bhinder, A., Carothers, S., & Ramaswamy, B. (2010) · Current Breast Cancer Reports · doi:10.1007/s12609-010-0005-5 · Cited by 3
Adjuvant chemotherapy in breast cancer
Bartsch, R., & Steger, G. G. (2008) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-008-0019-0 · Cited by 4
Resistance to HER2-Targeted Therapy
Theile, D., Lenz, G., Momand, J. A., & Kane, S. E. (2017) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-70142-4_2 · Cited by 4
Li, X., Yao, L., Wang, M., Wang, M., Li, X., Yu, X., Guo, J., Dong, H., Sun, X., & Xu, Y. (2020) · Journal of Breast Cancer · doi:10.4048/jbc.2020.23.e45 · Cited by 3
Carey, L. (2005) · Breast Diseases A Year Book Quarterly · doi:10.1016/s1043-321x(05)80145-6 · Cited by 3
Tumor Effect‐Site Pharmacokinetics: Mechanisms and Impact on Efficacy
Thurber, G. M. (2015) · Wiley eBooks · doi:10.1002/9780470571224.pse551 · Cited by 3
Targeted Auger electron radiotherapy of HER2-amplified breast cancer.
Costantini, D. L. (2009) · TSpace (University of Toronto) · Cited by 3
Suspected Neratinib Macular Toxicity Presenting As Macular Telangiectasia Type II
Enghelberg, M., & Kaifee, S. Q. (2023) · Cureus · doi:10.7759/cureus.33964 · Cited by 2
Metronomic Chemotherapy in Breast Cancer: Unleashing the Potential of Combination Regimens
Liu, J. H., Mo, H., Li, Q., Cazzaniga, M. E., & Ma, F. (2025) · Cancer Innovation · doi:10.1002/cai2.70035 · Cited by 3
Hsueh, S.-P., Hsu, W.-B., Wen, C.-C., & Wang, W.-B. (2011) · Cancer Gene Therapy · doi:10.1038/cgt.2011.55 · Cited by 2
Ma, X., Xue, L., Ou, K., Liu, X., Chen, J., Gao, L., & Yang, L. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e28923 · Cited by 4
A Fab of trastuzumab to treat HER2 overexpressing breast cancer brain metastases
Angeli, E., Paris, J., Tilly, O. L., Desvignes, C., Gapihan, G., Boquet, D., Pamoukdjian, F., Hamdan, D., Rigal, M., Poirier, F., et al. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00513-7 · Cited by 2
Breast Cancer: Radioimmunoscintigraphy and Radioimmunotherapy
Salouti, M., & Heidari, Z. (2011) · InTech eBooks · doi:10.5772/25293 · Cited by 2
Moschos, M. M., Chatziralli, I., Kalogeropoulos, C. D., Georgountzos, V., & Agapitos, E. B. (2013) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2012.0129 · Cited by 2
Resistance to Trastuzumab: Mechanistic Uncertainties
Park, J. W., & Michelle, M. E. (2002) · Clinical Breast Cancer · doi:10.1016/s1526-8209(11)70252-x · Cited by 2
Biological Therapies for Metastatic Breast Cancer: Antiangiogenesis
Harris, A. L., & Generali, D. (2007) · Springer eBooks · doi:10.1007/978-3-540-28266-2_33 · Cited by 2
Metadata
- Authors
- Izumi, Y., Xu, L., di Tomaso, E., Fukumura, D., & Jain, R. K.
- Affiliations
- Harvard University (US)
- Corresponding author
- Jain, Rakesh K.
- Venue
- Nature
- Published
- 2002-03
- Volume
- 416
- Issue
- 6878
- Pages
- 279-280
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2034801324
- Cited by
- 623
- References
- 11
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 26 · 2023: 10 · 2022: 14 · 2021: 12 · 2020: 18 · 2019: 12 · 2018: 20 · 2017: 23 · 2016: 18 · 2015: 24 · 2014: 27 · 2013: 30 · 2012: 35
- FWCI
- 12.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Cancer Institute (P01CA080124)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- trastuzumab, anti-angiogenic therapy, HER2, human epidermal growth factor receptor 2, tumor angiogenesis, tumor regression, combination therapy, breast cancer, monoclonal antibodies, tumor resistance
- MeSH terms
- Trastuzumab, Animals, Antibodies, Monoclonal, Humans, Lymphokines, Mammary Neoplasms, Experimental, Neovascularization, Pathologic, Signal Transduction, Gene Expression, Endothelial Growth Factors, Mice, SCID, Genes, erbB-2, Angiogenesis Inhibitors, Vascular Endothelial Growth Factors, Vascular Endothelial Growth Factor A, Mice, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.